Apellis Pharmaceuticals: A Good Product That Just Misses The Mark
Summarize this article with:
Edmund InghamInvesting Group LeaderFollow5ShareSavePlay(12min)CommentsSummaryApellis Pharmaceuticals, Inc. receives a Sell rating due to persistent revenue stagnation and profitability challenges for its key drug Syfovre.Syfovre faces safety setbacks, EU regulatory rejections, and fierce competition from Astellas’ Izervay, undermining blockbuster potential.APLS Q3 profitability was driven by a one-off royalty sale, not sustainable product growth; no forward guidance provided for 2025 or 2026.Management targets new kidney indications and awareness campaigns, but current pipeline and market dynamics cast doubt on long-term net profit prospects. RichVintage/E+ via Getty Images Investment Overview - Apellis Stock Hits Painful Lows In First Half Of 2025 My last two ratings on Apellis Pharmaceuticals, Inc. (APLS), the Waltham, Massachusetts-based pharma company and complement system specialist, have been Holds, the first beingThis article was written byEdmund Ingham14.43K FollowersFollowEdmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston BioHealth. The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, integrated financial statements, discounted cash flow analysis and market by market analysis. Learn more.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.Recommended For You